1374765-83-9

Upstream product

• 1350523-51-1 rac-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionitrile 
• 198477-89-3 1-(5-bromo-2-fluorophenyl)ethan-1-one 

Downstream Products

• 1266784-18-2 rac-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionic acid methyl ester 
• 1266784-23-9 (RS)-2-amino-2-(5-bromo-2-fluoro-phenyl)-propionic acid 
• 1266784-24-0 (RS)-2-amino-2-(5-bromo-2-fluoro-phenyl)-propan-1-ol 
• 1313525-71-1 2-(5-bromo-2-fluorophenyl)-2-(2-chloroacetylamino)propionic acid methyl ester 
• 1313525-72-2 3-(5-bromo-2-fluorophenyl)-1,3-dimethylpiperazine-2,5-dione 
• 1313525-73-3 3-(5-bromo-2-fluorophenyl)-1,3-dimethyl-5-thioxopiperazin-2-one 
• 1313525-74-4 5-amino-3-(5-bromo-2-fluorophenyl)-1,3-dimethyl-3,6-dihydro-1H-pyrazin-2-one 
• 1313525-75-5 [6-(5-bromo-2-fluorophenyl)-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl]carbamic acid tert-butyl ester 
• 1313525-76-6 [6-(5-amino-2-fluorophenyl)-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl]carbamic acid tert-butyl ester 
• 1313525-77-7 (6-{5-[(5-bromopyridine-2-carbonyl)amino]-2-fluorophenyl}-4,6-dimethyl-5-oxo-3,4,5,6-tetrahydropyrazin-2-yl)carbamic acid tert-butyl ester 
• 1313525-28-8 5-bromopyridine-2-carboxylic acid [3-(6-amino-2,4-dimethyl-3-oxo-2,3,4,5-tetrahydropyrazin-2-yl)-4-fluorophenyl]amide 
• 1313525-78-8 [6-(5-amino-2-fluorophenyl)-4,6-dimethyl-3,4,5,6-tetrahydropyrazin-2-yl]carbamic acid tert-butyl ester 
• 1313525-80-2 rac-[1-(5-bromo-2-fluoro-phenyl)-2-hydroxy-1-methyl-ethyl]-carbamic acid tert-butyl ester 
• 1313525-81-3 (R)-tert-butyl 4-(5-bromo-2-fluorophenyl)-4-methyl-1,2,3-oxathiazolidine-3-carboxylate 2,2-dioxide 

Relevant academic research and scientific papers

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 (“mGluR2”), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS

The present invention relates to novel triazolo[4,3-a]pyridine derivatives of Formula (I) wherein all radicals are as defined in the claims. The compounds according to the invention are positive allosteric modulators of the metabotropic glutamate receptor subtype 2 ("mGluR2"), which are useful for the treatment or prevention of neurological and psychiatric disorders associated with glutamate dysfunction and diseases in which the mGluR2 subtype of metabotropic receptors is involved. The invention is also directed to pharmaceutical compositions comprising such compounds, to processes to prepare such compounds and compositions, and to the use of such compounds for the prevention or treatment of neurological and psychiatric disorders and diseases in which mGluR2 is involved.

PYRAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS

The invention relates to novel heterocyclic compounds of the formula (I) in which all of the variables are as defined in the specification, in free form or in salt form, to their preparation, to their medical use and to medicaments comprising them.